Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 10, 2026 16:09 ET | Source: Mesoblast Limited

Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION

Working with Parent Project Muscular Dystrophy and the Duchenne Registry on patient identification and trial awareness efforts ~15,000 children are living with DMD in the U.S. NEW YORK, April 10,...
April 08, 2026 09:07 ET | Source: Mesoblast Limited

Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation

Mesoblast outlines commercial strategy to double net revenues as Ryoncil® approaches US$100M net revenue milestone since launch last year Showcases transformative blockbuster products for...
April 07, 2026 23:35 ET | Source: Mesoblast Limited

Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy

Partnering with Parent Project Muscular Dystrophy to ensure timely access to the trial for eligible patients ~15,000 children are living with DMD in the U.S. NEW YORK, April 07, 2026 (GLOBE...
April 06, 2026 21:03 ET | Source: Mesoblast Limited

Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter

Strong growth in February/March following January seasonality Net revenue approaches US$100M since launch NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB),...
March 17, 2026 19:19 ET | Source: Mesoblast Limited

Mesoblast to Host R&D Day on April 8, 2026

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host its inaugural R&D Day...
March 11, 2026 19:21 ET | Source: Mesoblast Limited

Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of...
February 26, 2026 19:42 ET | Source: Mesoblast Limited

Ryoncil® Profits Underpinning Substantial Growth Pipeline

NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and...
February 20, 2026 07:00 ET | Source: Mesoblast Limited

Mesoblast Financial Results and Corporate Update Webcast

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss...
February 11, 2026 18:27 ET | Source: Mesoblast Limited

High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD

NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided data presented at the...
January 28, 2026 18:54 ET | Source: Mesoblast Limited

Ryoncil® Net Revenues Increase for the Quarter to US$30M

NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its...